## IONS: Ionis Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.9% below STRENGTH zone (4.0-10.0%); PEG 25.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.81)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. RBC Capital Raises Price Target for Ionis Pharmaceuticals (IONS) to $95 | IONS Stock News**
- Source: GuruFocus | 20251217T160839 | Bullish | Relevance: 100%
- RBC Capital has maintained its 'Outperform' rating on Ionis Pharmaceuticals (IONS) and significantly increased its price target from $82 to $95, reflecting strong confidence in the company's future. This move aligns with a trend of consistent price target raises from various analysts, signaling positive sentiment and growth potential for the leading developer of antisense technology. Ionis Pharmaceuticals has brought several novel drugs to market and has an average analyst target price of $84.42, implying an upside from its current price.

**2. Sicart Associates LLC Has $10.75 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS**
- Source: MarketBeat | 20251217T120839 | Somewhat-Bullish | Relevance: 100%
- Sicart Associates LLC reduced its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 11.3% in Q3, now holding 164,318 shares valued at $10.75 million. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average target price of $86.19. The company has shown strong quarterly revenue growth and exceeded EPS estimates, with institutional investors owning a significant portion of its shares.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | RBC Capital | $95 | $82 | +16% |
| 2025-12-15 | Leerink Partner | $100 | $85 | +18% |
| 2025-12-09 | B of A Securiti | $97 | $86 | +13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-15 | Leerink Partner | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($8.92M) |
| Sells | 20 ($5.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- FMR, LLC: 14.6% (+0.2%)
- Vanguard Group Inc: 10.2% (-1.4%)
- T. Rowe Price Invest: 8.1% (-18.0%)
- Capital World Invest: 7.8% (+1.5%)
- Blackrock Inc.: 6.5% (-4.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.0% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.9M in recent transactions.
3. Valuation stretched: PEG 25.7x requires aggressive growth execution.
4. Elevated short interest (12.7%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 3 raises (avg +15%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 25.70 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.8x). Analyst sentiment positive (3 raises, avg +15%). Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $12.9B |
| Beta | 0.30 |
| 52W Range | $23.95 - $83.61 |
| Short Interest | 12.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 25.70 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 1.1% to -0.9% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.9pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.60x) but short-term weakness (below SMA20). MACD histogram bearish (-0.60), momentum weakening. RSI neutral at 56. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.90% (CS: 40) | Neutral |
| RSI_14 | 55.6 | Neutral |
| MACD Histogram | -0.60 | Bearish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 1.053x | Above |
| vs SMA200 | 1.597x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $79.57
- **Stop Loss:** $74.81 (6.0% risk)
- **Target:** $84.33 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 252
- **Position Value:** $20,051.64
- **Portfolio %:** 20.05%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.05 | $-0.61 | +41.8% |
| 2025Q2 | $0.16 | $0.85 | +415.1% |
| 2025Q1 | $-1.03 | $-0.92 | +10.4% |
| 2024Q4 | $-0.84 | $-0.43 | +49.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*